Literature DB >> 28616119

New research in bladder cancer, ASCO-GU 2017.

Peter C Black1, Srikala Sridhar2.   

Abstract

Entities:  

Year:  2017        PMID： 28616119      PMCID： PMC5461153          DOI： 10.5489/cuaj.4606

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  2 in total

1.  Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.

Authors:  Neal D Shore; Stephen A Boorjian; Daniel J Canter; Kenneth Ogan; Lawrence I Karsh; Tracy M Downs; Leonard G Gomella; Ashish M Kamat; Yair Lotan; Robert S Svatek; Trinity J Bivalacqua; Robert L Grubb; Tracey L Krupski; Seth P Lerner; Michael E Woods; Brant A Inman; Matthew I Milowsky; Alan Boyd; F Peter Treasure; Gillian Gregory; David G Sawutz; Seppo Yla-Herttuala; Nigel R Parker; Colin P N Dinney
Journal:  J Clin Oncol       Date:  2017-08-23       Impact factor: 44.544

2.  Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.

Authors:  Jose Luis Perez-Gracia; Yohann Loriot; Jonathan E Rosenberg; Thomas Powles; Andrea Necchi; Syed A Hussain; Rafael Morales-Barrera; Margitta M Retz; Günter Niegisch; Ignacio Durán; Christine Théodore; Enrique Grande; Xiaodong Shen; Jingjing Wang; Betty Nelson; Christina L Derleth; Michiel S van der Heijden
Journal:  Eur Urol       Date:  2017-12-20       Impact factor: 20.096
  2 in total
  1 in total

1.  CD40 is Positively Correlated with the Expression of Nucleophosmin in Cisplatin-Resistant Bladder Cancer.

Authors:  Chenshuo Luo; Ting Lei; Man Zhao; Qian Meng; Man Zhang
Journal:  J Oncol       Date:  2020-04-28       Impact factor: 4.375
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.